溶瘤病毒作为抗原非特异性癌症疫苗。
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines.
机构信息
Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
出版信息
Cancer Cell. 2018 Apr 9;33(4):599-605. doi: 10.1016/j.ccell.2018.03.011.
Abstract
Selective destruction of neoplastic tissues by oncolytic viruses (OVs) leads to antigen-agnostic boosting of neoantigen-specific cytotoxic T lymphocyte (CTL) responses, making OVs ideal companions for checkpoint blockade therapy. Here we discuss the mechanisms whereby OVs modulate both adjuvanticity and antigenicity of tumor cells. Suppression of antitumor immunity after OV therapy has not been observed, possibly because viral antigen expression diminishes as the antiviral response matures, thereby progressively honing the CTL response to tumor neoantigens. By combining direct in situ tumor destruction with the ability to boost antitumor immunity, OVs also have the potential to be powerful standalone cancer therapies.
摘要
溶瘤病毒（OVs）选择性地破坏肿瘤组织，导致新抗原特异性细胞毒性 T 淋巴细胞（CTL）反应的抗原不可知增强，使 OVs 成为检查点阻断治疗的理想伴侣。在这里，我们讨论了 OV 调节肿瘤细胞的佐剂和抗原性的机制。在 OV 治疗后没有观察到抗肿瘤免疫的抑制，这可能是因为随着抗病毒反应的成熟，病毒抗原的表达减少，从而逐渐使 CTL 对肿瘤新抗原的反应得到增强。通过将直接原位肿瘤破坏与增强抗肿瘤免疫的能力相结合，OVs 也有可能成为强大的独立癌症治疗方法。
相似文献
1
Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines.溶瘤病毒作为抗原非特异性癌症疫苗。
Cancer Cell. 2018 Apr 9;33(4):599-605. doi: 10.1016/j.ccell.2018.03.011.
2
Arming oncolytic viruses to leverage antitumor immunity.武装溶瘤病毒以利用抗肿瘤免疫力。
Expert Opin Biol Ther. 2015 Jul;15(7):959-71. doi: 10.1517/14712598.2015.1044433. Epub 2015 May 10.
3
Oncolytic Viruses in Cancer Treatment: A Review.溶瘤病毒在癌症治疗中的应用：综述。
JAMA Oncol. 2017 Jun 1;3(6):841-849. doi: 10.1001/jamaoncol.2016.2064.
4
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.辅助溶瘤病毒治疗用于个体化抗肿瘤免疫治疗。
Nat Commun. 2021 May 11;12(1):2626. doi: 10.1038/s41467-021-22929-z.
5
Oncolytic HSV Vectors and Anti-Tumor Immunity.溶瘤单纯疱疹病毒载体与抗肿瘤免疫。
Curr Issues Mol Biol. 2021;41:381-468. doi: 10.21775/cimb.041.381. Epub 2020 Sep 17.
6
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.溶瘤病毒联合癌症免疫治疗：开创新一代癌症治疗。
Front Immunol. 2020 Apr 28;11:683. doi: 10.3389/fimmu.2020.00683. eCollection 2020.
7
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.一种模块化的自佐剂癌症疫苗与溶瘤疫苗联合使用可诱导强烈的抗肿瘤免疫。
Nat Commun. 2021 Aug 31;12(1):5195. doi: 10.1038/s41467-021-25506-6.
8
Oncolytic viruses as therapeutic cancer vaccines.溶瘤病毒作为治疗性癌症疫苗。
Mol Cancer. 2013 Sep 11;12(1):103. doi: 10.1186/1476-4598-12-103.
9
A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy.理性的关联：溶瘤病毒疫苗作为过继性 T 细胞疗法的功能伙伴。
Cytokine Growth Factor Rev. 2020 Dec;56:149-159. doi: 10.1016/j.cytogfr.2020.07.003. Epub 2020 Jul 3.
10
Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines.通过感染细胞疫苗调节自然杀伤细胞治疗转移性疾病。
Viruses. 2019 May 11;11(5):434. doi: 10.3390/v11050434.
引用本文的文献
1
Harnessing immunotherapy: cancer vaccines as novel therapeutic strategies for brain tumor.利用免疫疗法：癌症疫苗作为脑肿瘤的新型治疗策略
Front Immunol. 2025 Jul 17;16:1588081. doi: 10.3389/fimmu.2025.1588081. eCollection 2025.
2
Gnostic and agnostic immunotherapy by tropism-retargeted herpes simplex virus without direct tumor treatment.通过嗜性重定向单纯疱疹病毒进行的无需直接肿瘤治疗的知性感和不可知感免疫疗法。
J Immunother Cancer. 2025 Jul 22;13(7):e011812. doi: 10.1136/jitc-2025-011812.
3
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
4
Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms.肺癌疫苗策略：探索从传统平台到基于RNA平台的范围
Front Bioeng Biotechnol. 2025 Jun 23;13:1617352. doi: 10.3389/fbioe.2025.1617352. eCollection 2025.
5
Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice.中和性单克隆抗体可改善人CD46转基因小鼠体内静脉注射溶瘤腺病毒的生物分布。
PLoS One. 2025 Jun 25;20(6):e0326857. doi: 10.1371/journal.pone.0326857. eCollection 2025.
6
Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer.癌症光疗法与免疫疗法的临床结果及财务方面的比较分析
Adv Sci (Weinh). 2025 Aug;12(30):e17657. doi: 10.1002/advs.202417657. Epub 2025 Jun 19.
7
From infection to tumor: genetic evidence of viral antibody immune response' role in urologic cancer development.从感染到肿瘤：病毒抗体免疫反应在泌尿系统癌症发展中作用的遗传学证据
Discov Oncol. 2025 May 29;16(1):947. doi: 10.1007/s12672-025-02768-w.
8
Translational Advances in Oncogene and Tumor-Suppressor Gene Research.癌基因与肿瘤抑制基因研究的转化进展
Cancers (Basel). 2025 Mar 17;17(6):1008. doi: 10.3390/cancers17061008.
9
Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation.溶瘤病毒作为癌症治疗手段：从机制洞察到临床转化
Mol Ther. 2025 May 7;33(5):2217-2228. doi: 10.1016/j.ymthe.2025.03.035. Epub 2025 Mar 25.
10
Cancer Vaccines: A Novel Revolutionized Approach to Cancer Therapy.癌症疫苗：一种全新的癌症治疗变革方法。
Indian J Clin Biochem. 2025 Apr;40(2):191-200. doi: 10.1007/s12291-024-01201-3. Epub 2024 Mar 15.
本文引用的文献
1
Designing and building oncolytic viruses.设计和构建溶瘤病毒。
Future Virol. 2017 Apr;12(4):193-213. doi: 10.2217/fvl-2016-0129. Epub 2017 Mar 31.
2
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.细胞死亡的分子机制：细胞死亡命名委员会 2018 年的建议。
Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23.
3
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.静脉注射溶瘤单纯疱疹病毒(reovirus)至脑肿瘤患者，可使其对后续检查点阻断产生免疫原性。
Sci Transl Med. 2018 Jan 3;10(422). doi: 10.1126/scitranslmed.aam7577.
4
Necroptotic cell death in anti-cancer therapy.在癌症治疗中的细胞坏死性细胞死亡。
Immunol Rev. 2017 Nov;280(1):207-219. doi: 10.1111/imr.12583.
5
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.随机、开放标签的 II 期研究评估了替莫唑胺联合伊匹单抗与伊匹单抗单药治疗晚期不可切除黑色素瘤患者的疗效和安全性。
J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5.
6
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.溶瘤病毒疗法可促进肿瘤内T细胞浸润并改善抗PD-1免疫疗法。
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.
7
Mitotic progression following DNA damage enables pattern recognition within micronuclei.DNA损伤后的有丝分裂进程能够实现微核内的模式识别。
Nature. 2017 Aug 24;548(7668):466-470. doi: 10.1038/nature23470. Epub 2017 Jul 31.
8
cGAS surveillance of micronuclei links genome instability to innate immunity.cGAS对微核的监测将基因组不稳定性与先天免疫联系起来。
Nature. 2017 Aug 24;548(7668):461-465. doi: 10.1038/nature23449. Epub 2017 Jul 24.
9
Innate Immune Receptors as Competitive Determinants of Cell Fate.作为细胞命运竞争决定因素的天然免疫受体
Mol Cell. 2017 Jun 15;66(6):750-760. doi: 10.1016/j.molcel.2017.05.009.
10
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.溶瘤性水疱性口炎病毒引发对免疫肿瘤治疗的不同反应。
Mol Ther. 2017 Aug 2;25(8):1917-1932. doi: 10.1016/j.ymthe.2017.05.006. Epub 2017 Jun 2.
Zotero 插件